Purification apparatus and method for pharmaceutical excipient grade R134a
By employing a multi-stage coupled process involving condensation, degassing tower, distillation tower, and gradient fluorination-modified activated carbon, the problem of removing trace impurities in pharmaceutical-grade R134a was solved, enabling the stable production of high-purity pharmaceutical-grade R134a and meeting pharmaceutical requirements.
Patent Information
- Application Number
- CN202611139559.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-30
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2046-07-30
AI Technical Summary
Existing technologies are unable to effectively remove trace amounts of toxic impurities R1122 and moisture from pharmaceutical grade R134a, resulting in substandard product purity. Furthermore, conventional adsorbents have poor selectivity and low capacity, making it impossible to guarantee the stability of continuous production.
A purification method is adopted, which involves condensation to remove non-condensable gases, degassing tower to remove light gases, distillation tower to remove heavy gases, and gradient fluorination-modified activated carbon for deep adsorption. The targeted deep removal of R1122 is achieved through gradient fluorination-modified activated carbon, and the multi-stage coupling process ensures the impurity removal effect.
It achieves a purity of ≥99.99% for pharmaceutical excipient-grade R134a, no detection of R1122, and moisture content ≤3ppm. It exhibits high quality stability, large adsorption capacity, and is not easily penetrated, thereby reducing production costs and material consumption.
Smart Images

Figure CN122643717B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of fluorinated hydrocarbon refining and purification technology, specifically to a purification apparatus and method for pharmaceutical grade R134a. Background Technology
[0002] 1,1,1,2-Tetrafluoroethane (R134a) is a high-performance hydrofluorocarbon compound widely used in various fields due to its advantages such as being non-toxic, odorless, non-flammable, chemically stable, and having a zero ozone depletion potential (ODP). In recent years, with the rapid upgrading of the pharmaceutical industry, the demand for R134a, as a non-ozone-depleting environmentally friendly propellant, has experienced explosive growth in the fields of pharmaceutical aerosols (such as metered-dose inhalers (MDI)), cryogenic cooling media, and drug synthesis carriers.
[0003] As a pharmaceutical excipient that directly enters the human body, pharmaceutical-grade R134a imposes extremely stringent requirements on purity and impurity content. Its purity must consistently reach above 99.99%, and impurities such as non-condensable gases, moisture, fluorocarbon isomers, and olefins must be controlled at extremely low levels (typically below ppm). It is particularly important to note that industrial-grade R134a is usually produced from trichloroethylene and other raw materials through a fluorination reaction, resulting in extremely complex reaction byproducts. Among these, 1,1,2,2-tetrafluoroethane (R134) and 1,1-difluoro-2-chloroethylene (R1122), as typical unsaturated fluoroolefins and isomers, possess certain physiological toxicity and high chemical reactivity. R1122, especially, containing double bonds, easily reacts with the active pharmaceutical ingredient in aerosols, directly affecting the long-term stability of the drug and patient safety. Therefore, pharmacopoeias and industry standards in various countries require its removal to below the detection limit (typically <1 ppm).
[0004] However, existing purification technologies face significant technical bottlenecks in removing R134 and R1122: First, the boiling point difference between R134a (boiling point -26.1℃) and R1122 (boiling point -17.7℃) is about 8.5℃. Although there is a certain difference, due to their mutual solubility in the chlorofluorocarbon system and the tendency to form narrow boiling points, an ultra-high theoretical plate number and an extremely high reflux ratio are required to control R1122 to <1ppm.
[0005] Secondly, to compensate for the shortcomings of distillation, existing technologies often use molecular sieves or ordinary activated carbon for adsorption. However, conventional adsorbents have fatal flaws: due to the lack of directional pore size control and surface modification, their selectivity is extremely poor. While adsorbing trace amounts of R1122, they also co-adsorb large amounts of the target product R134a, resulting in significant product yield loss; moreover, ordinary adsorbents have extremely low adsorption capacity for R1122, and the bed is easily permeated, making it impossible to guarantee the stability of continuous production. Some studies have attempted to modify activated carbon with fluorination, but when conventional one-step methods directly introduce high-concentration or even pure hydrogen fluoride gas for treatment, the intense exothermic reaction and strong corrosive etching effect often lead to severe collapse of the activated carbon's microporous structure, a sharp reduction in specific surface area, and ultimately, a loss of adsorption and separation capacity.
[0006] For the reasons mentioned above, China still heavily relies on imports for high-quality pharmaceutical-grade R134a, resulting in high procurement costs and supply chain risks. Therefore, there is an urgent need to develop a pharmaceutical-grade R134a purification device and method with a reasonable process flow that can accurately target and remove R1122 and other trace impurities. Summary of the Invention
[0007] In view of the shortcomings of the prior art, the purpose of this invention is to provide a purification method for pharmaceutical grade R134a, which uses the technical route of condensation to remove non-condensable gas + degassing tower to remove light gas + distillation tower to remove heavy gas + gradient fluorination modified activated carbon for deep adsorption, thus solving the problem of targeted deep removal of trace toxic impurities R1122.
[0008] Another objective of this invention is to provide a purification device for pharmaceutical excipient grade R134a, in which each unit relies on each other and works synergistically to systematically eliminate various impurities that affect pharmaceutical excipient grade indicators, ultimately obtaining a high-quality product with a purity ≥99.99%, R1122 not detected, and moisture ≤3ppm, exhibiting high quality stability.
[0009] This invention is achieved using the following technical solution: The purification method for pharmaceutical excipient grade R134a includes the following steps: (1) The industrial grade R134a crude raw material is fed into the primary condenser for condensation treatment to remove non-condensable gases and obtain liquid crude product. (2) The liquid crude product is fed into a degassing tower for distillation and degassing to remove light component impurities; (3) The material after the removal of light components is fed into the distillation column for deep distillation to remove heavy components and fluorocarbon isomer impurities, and the gaseous product is obtained from the top of the distillation column; (4) After the gaseous product is condensed into a liquid phase, it is fed into an adsorber filled with gradient fluorinated modified activated carbon for deep adsorption, selectively removing R1122 impurities and moisture to obtain the pharmaceutical excipient grade R134a product. The preparation method of the gradient fluorination modified activated carbon includes: using activated carbon as a substrate, pretreating it with a mixed gas of hydrogen fluoride and nitrogen; then gradually increasing the proportion of hydrogen fluoride and decreasing the proportion of nitrogen in the introduced gas in stages to carry out gradient concentration and temperature increase modification; finally switching to pure hydrogen fluoride gas for deep fluorination treatment at 200-240℃, and obtaining the gradient fluorination modified activated carbon after cooling.
[0010] Preferably, the specific operating parameters for steps (1) to (3) are as follows: In step (1), the temperature of the condensation treatment is controlled at -10 to 20°C and the pressure is controlled at 0.35 to 0.45 MPa. The condensation mechanism under these parameters is that R134a can be fully liquefied under these temperature and pressure conditions, while non-condensable gases such as oxygen and nitrogen remain in a gaseous state, thereby efficiently and with low energy consumption by using the principle of gas-liquid phase separation to discharge them from the system.
[0011] In step (2), the operating pressure of the degassing tower is controlled at 0.8-1.4 MPa, the bottom temperature is controlled at 35-65℃, and the top temperature is controlled at 15-45℃. This operating condition aims to increase the relative volatility of light components such as R143a and R134a, so that the light components are enriched at the top of the tower and discharged.
[0012] In step (3), the operating pressure of the distillation column is controlled at 0.5-1.2 MPa, the bottom temperature is controlled at 40-60℃, and the top temperature is controlled at 30-50℃. In this stage, precision distillation is used to remove some high-boiling-point fluorocarbon isomers and heavy components such as R134, and high-purity R134a gas phase is collected from the top of the column.
[0013] Preferably, in step (4), the operating pressure of the adsorber is controlled at 0.4-1.0 MPa and the operating temperature is controlled at 10-40℃; the product adsorbed by the adsorber is tested online, qualified products are collected in the finished product tank, and unqualified products are sent back to the degassing tower as reflux material for further purification.
[0014] Furthermore, the present invention provides a method for preparing a core material, namely gradient fluorinated modified activated carbon, comprising: using activated carbon as a substrate, pretreating it with a mixed gas of hydrogen fluoride and nitrogen; then gradually increasing the proportion of hydrogen fluoride and decreasing the proportion of nitrogen in the introduced gas in stages to perform gradient concentration and temperature-increasing modification; finally switching to pure hydrogen fluoride gas for deep fluorination treatment, and obtaining gradient fluorinated modified activated carbon after cooling.
[0015] The specific preparation steps are as follows: S1. Dry the activated carbon at 100-120℃ for 4-6 hours to completely remove the physically adsorbed moisture and volatile impurities and open up the pores. S2. Take 200g of YH-GW09 activated carbon and load it into an Inconel 600 fluorination reactor with an inner diameter of 50mm and a height of 800mm. The bed height is about 400mm.
[0016] S3, with a total gas flow rate of 500 mL / min (corresponding to a space velocity GHSV = 150 h⁻¹). -1 A mixed gas with a volume ratio of HF:N2=50:250 is introduced and pretreated at 120-160℃ for 2-3 hours. S4. Adjust the volume ratio of the mixed gas to HF:N2 = 100:200, 150:150, and 250:50 in stages, and keep it heated for 1-2 hours in each stage. S5. Finally, switch to pure HF gas and keep at 200-240℃ for deep fluorination for 3-4 hours. S6. After the reaction is complete, purge with nitrogen and cool to room temperature.
[0017] The mechanism of action of gradient fluorination modified activated carbon in this invention is analyzed as follows: Conventional one-step high-concentration fluorination methods suffer from a violent hydrogen fluoride (HF) reaction, which releases a large amount of heat and produces intense surface etching, directly causing the activated carbon micropore walls to burn through, pore size to collapse, and a significant decrease in specific surface area. This invention employs a process of low-concentration HF initiation, multi-stage gradient concentration, and deep fluorination with pure HF. In the initial low-concentration stage, a large amount of inert nitrogen gas plays a role in dilution and heat transfer. The low-concentration HF gently activates and slightly etches the carbon skeleton at the edges, cleaning the amorphous carbon in the pores. As the HF concentration and temperature increase in stages, fluorine atoms gradually replace the oxygen-containing functional groups (such as hydroxyl and carboxyl groups) on the surface of activated carbon. After the activated carbon is dried at high temperature in S1 to remove free water from the pores, the low-temperature, low-concentration HF pretreatment in S2 can activate the oxygen-containing functional groups such as hydroxyl and carboxyl groups on the carbon surface. In the subsequent deep fluorination stage of pure HF at 200-240℃, HF undergoes an addition reaction with the unsaturated carbon atoms at the edge of the carbon skeleton, and on the other hand, it undergoes a substitution reaction in situ catalyzed by the trace metal impurities remaining in the activated carbon preparation process, stably generating CF covalent bonds on the surface of the carbon material. Fluorination modification can be completed without elemental F2. Finally, deep chemical modification is completed under pure HF and high temperature. Due to the mild pore expansion and skeleton stabilization in the early stage, the overall porous structure of the activated carbon is preserved.
[0018] After the aforementioned gradient fluorination, the pore size distribution of the activated carbon was precisely controlled within the 0.6-0.9 nm range. This pore size range perfectly matches the molecular dynamics diameter of R1122, while creating steric hindrance for R134a, which has a more three-dimensional spatial configuration and a slightly larger molecular diameter. Furthermore, the R1122 molecule (1,1-difluoro-2-chloroethylene) has a double bond structure and highly polar chlorine atoms, exhibiting a unique dipole moment and π electron cloud; while the modified activated carbon surface is enriched with highly electronegative CF bond groups. Based on the principles of like dissolves like and polar induction, it is speculated that the modified surface exhibits enhanced nonpolarity, repelling the less polar R134a, while the adsorption of R1122 mainly relies on pore size sieving and van der Waals forces.
[0019] In a second aspect, the present invention provides a purification apparatus for pharmaceutical-grade R134a to implement the above-described method, comprising an industrial-grade R134a finished product tank, a primary separator condenser, a feed pump, a degassing tower, a distillation tower, a finished product condenser, an adsorber, and a pharmaceutical-grade finished product tank connected in sequence by pipelines.
[0020] The upper inlet of the primary condenser is connected to the industrial-grade R134a finished product tank, and the lower outlet is connected to the degassing tower via the feed pump; the bottom outlet of the degassing tower is connected to the inlet of the distillation tower, the top outlet of the distillation tower is connected to the finished product condenser, and the bottom outlet of the finished product condenser is connected to the adsorber; the adsorber is specially filled with the gradient fluorinated modified activated carbon prepared in this invention.
[0021] Preferably, the upper outlet pipeline of the adsorber is divided into two paths. The first path connects to the finished product tank for pharmaceutical excipients and is used to transport qualified products. The second path serves as a return line for unqualified products, flowing back to the degassing tower. This design automatically returns the material to the front-end system when the adsorbent is nearing the end of its use or when system fluctuations cause abnormal indicators, preventing unqualified products from mixing into the finished pharmaceutical excipients.
[0022] A three-way valve is installed on the adsorber outlet line, connecting to an online gas chromatograph (FV-3320, equipped with an FID detector and Al2O3 and Gaspro capillary columns, 60m in length). Automatic sampling is performed every 40 minutes to detect R1122 content (limit of quantitation 0.5ppm) and R134 content (limit of quantitation 1ppm). A Michell Easidew PRO XP dew point meter is also installed to monitor moisture content.
[0023] Control logic: When R1122 < 1 ppm, R134 < 5 ppm, and moisture < 5 ppm, the valve switches to the first path, and the product enters the pharmaceutical excipient-grade finished product tank; if any indicator exceeds the standard, the valve automatically switches to the second path, and the material flows back to the degassing tower inlet.
[0024] Preferably, both the degassing tower and the distillation tower are equipped with sampling ports for real-time monitoring of the component quality of the gas and liquid phase materials.
[0025] Preferably, the main body of the purification device system of this invention (including towers, storage tanks, and heat exchangers) and the pipes and valves in contact with the materials are all made of SS304 or 316L stainless steel; however, the fluorination reactor used to prepare the gradient fluorinated modified activated carbon uses Inconel 600 alloy, and some flange sealing surfaces are made of 16MnⅢ weld overlay Inconel 600 material. This eliminates secondary pollution to pharmaceutical excipients caused by rusting of ordinary carbon steel or leaching of metal ions from the hardware level, while avoiding the risk that certain metals may catalyze the trace decomposition of R134a, thus meeting the GMP hardware hygiene requirements for pharmaceutical excipient products.
[0026] Compared with the prior art, the beneficial effects of the present invention are: (1) This invention achieves a synergistic effect mechanism of size sieving + polar adsorption by precisely controlling the pore size and surface chemical polarity, thus realizing the exclusive targeted adsorption of the purified impurity R1122. It has a high removal efficiency, large adsorption capacity and is not easy to penetrate, and can stably reduce the R1122 in the raw material from tens of ppm to below the detection limit, solving the industry problem that conventional distillation cannot separate near-boiling impurities.
[0027] (2) The present invention adopts a gradient concentration and heating fluorination process, which avoids the violent exothermic and pore collapse phenomena caused by conventional direct high-concentration fluorination, and preserves the specific surface area and mechanical strength of the adsorbent material to the greatest extent. The material has a long service life and excellent regeneration performance, which reduces the operating cost of continuous industrial production.
[0028] (3) This invention proposes a multi-stage coupled continuous process: initial condensation to remove non-condensable gases, dual-tower distillation to remove light and heavy components, and fine adsorption to remove trace amounts of olefins and water. Each unit relies on each other and works synergistically to systematically eliminate various impurities that affect pharmaceutical-grade indicators. Ultimately, a high-quality product with a purity ≥99.99%, R1122 not detected, and moisture ≤3ppm is stably obtained, exhibiting high quality stability. The entire system uses high-grade stainless steel and a sealed, leak-proof design to eliminate the risk of secondary pollution and catalytic degradation; online monitoring and a non-conforming product return mechanism realize closed-loop control of purified materials, ensuring production safety and product qualification rate. Attached Figure Description
[0029] Figure 1 This is a schematic diagram of the purification apparatus for pharmaceutical grade R134a of the present invention.
[0030] Figure 2XPS fluorine spectra of the gradient fluorinated modified activated carbon prepared in Example 1 of this invention and the unmodified activated carbon in Comparative Example 1.
[0031] Figure 3 This is a GC gas chromatogram of the raw material R134a used in Example 1 of the present invention.
[0032] Figure 4 This is a GC gas chromatogram of the purified pharmaceutical excipient grade R134a from Example 1 of the present invention.
[0033] In the diagram: 1. Industrial-grade R134a finished product tank; 2. Preliminary condenser; 3. Feed pump; 4. Degassing tower; 5. Distillation tower; 6. Finished product condenser; 7. Adsorber; 8. Pharmaceutical excipient-grade finished product tank. Detailed Implementation
[0034] The present invention will now be described in further detail with reference to the accompanying drawings and technical principles. It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the scope of protection of the present invention.
[0035] Sources and specifications of raw materials and reagents (1) Industrial grade R134a crude raw material: Industrial grade R134a (batch number 125051854) produced by Shandong Dongyue Green Cold Technology Co., Ltd. was used. According to GB / T18826-2015, the purity was 99.90% (gas chromatography method), and the impurity content was: R134 470ppm, R1122 12.3ppm, moisture 4.4ppm (Karl Fischer method), and non-condensable gas 0.45% (volume fraction).
[0036] (2) Activated carbon substrate: Petrochemical-grade activated carbon, model YH-GW09, produced by Chengde Rehe Activated Carbon Co., Ltd. The specific surface area was tested to be 1120 m². 2 / g (BET method), iodine adsorption value ≥980 mg / g, abrasion resistance ≥96%, ignition residue ≤3.5%, drying weight loss ≤10%.
[0037] (3) Gaseous reagents: Hydrogen fluoride (HF) gas, purity ≥99.9%; Nitrogen (N2), high-purity nitrogen (obtained by vaporization of liquid nitrogen), purity ≥99.999%.
[0038] I. Structure of the Purification Unit like Figure 1As shown, this invention provides a purification device for pharmaceutical grade R134a. The upper inlet of the primary condenser 2 is connected to the industrial grade R134a finished product tank 1, and a non-condensable gas venting pipeline is provided at the top of the primary condenser. The lower outlet is connected to the inlet of the degassing tower 4 via a feed pump 3. The top of the degassing tower 4 is provided with a light component outlet, and its bottom outlet is connected to the inlet of the distillation tower 5. The bottom of the distillation tower 5 is provided with a heavy component outlet, and its top outlet is connected to the finished product condenser 6. The bottom outlet of the finished product condenser 6 is connected to the bottom or top inlet of the adsorber 7.
[0039] The outlet pipeline of adsorber 7 is divided into two lines, and the valves are switched by an online chromatograph: the first line is connected to the pharmaceutical excipient-grade finished product tank 8 to receive qualified products; the second line serves as a reflux line for unqualified products, flowing back to degassing tower 4. Both degassing tower 4 and distillation tower 5 have multiple sampling ports along their height. To meet pharmaceutical excipient-grade GMP hygiene standards, the entire system's main body, pipes, and valves are made of SS304 or 316L stainless steel to avoid secondary contamination caused by rust particles and metal ion catalysis from carbon steel.
[0040] II. Purification Process Flow This invention employs a multi-stage coupled process: condensation to remove non-condensable gases, dual-tower distillation to remove light and heavy components, and directional modification and adsorption to remove near-boiling isomers. The mechanisms of each step are as follows: (1) Initial separation and condensation to remove non-condensable gases: Industrial-grade R134a feedstock typically contains non-condensable gases such as oxygen and nitrogen. If these gases enter subsequent distillation columns, they will severely affect the gas-liquid phase balance within the column and increase the condensation load. This step controls the condensation temperature to -10 to -20°C and the pressure to 0.35 to 0.45 MPa. Under these specific temperature and pressure conditions, R134a exceeds its dew point and liquefies in large quantities, while oxygen, nitrogen, and other gases remain in a superheated gaseous state. Through physical phase change, the gaseous non-condensable gases are discharged from the top, and the crude liquid R134a is pumped to the next process, achieving a low-energy, high-efficiency initial separation.
[0041] (2) Removal of light and heavy components by double-tower distillation: The liquid crude product enters degassing column 4. Under an operating pressure of 0.8-1.4 MPa, the light components, such as R143a, are collected from the top of the column by utilizing the boiling point difference between R134a and other light components. The bottom product is fed into distillation column 5, where it is distilled at 0.5-1.2 MPa to remove heavy components with higher boiling points and some high-boiling-point fluorocarbon isomers. High-purity R134a gas is collected from the top of the column. However, at this stage, because R134 (1,1,2,2-tetrafluoroethane) and R1122 (1,1-difluoro-2-chloroethylene) easily form an azeotropic system with R134a, even with a high number of theoretical plates in traditional distillation, it is difficult to remove it to below 1 ppm, relying on subsequent deep targeted adsorption.
[0042] (3) Preparation of graded fluorination modified activated carbon: The R134a gas drawn from the top of the distillation column is condensed and then enters adsorber 7, which is filled with the gradient fluorinated modified activated carbon prepared in this invention. This material is the core for achieving deep removal of R1122, and its preparation process and mechanism of action are as follows: First, the activated carbon substrate is dried at 100-120℃ to thoroughly remove moisture and physically adsorbed impurities from the pores.
[0043] Gradient fluorination modification is then carried out: if high-concentration HF is directly introduced, the violent exothermic reaction will instantly burn through the carbon skeleton, causing micropore collapse and loss of specific surface area. This invention adopts a gradient method with low concentration starting, staged concentration enhancement, and pure gas finishing.
[0044] Initially (HF:N2=50:250, 120-160℃), a large amount of nitrogen is used as a diluent and heat transfer medium, while low-concentration HF gently etches the surface of activated carbon, clearing the amorphous carbon blocking the pores and initially opening and regulating the channels.
[0045] In the medium term (with the HF ratio gradually increasing and the temperature stepwise rising), as the HF concentration increases, fluorine atoms begin to steadily replace oxygen-containing functional groups (such as hydroxyl and carboxyl groups) on the surface of activated carbon.
[0046] Later (pure HF, 200-240℃), deep chemical modification was carried out in a high-temperature pure fluorine environment to form extremely stable CF covalent bonds on the carbon skeleton surface.
[0047] The actual purification effect of the present invention will be verified by specific embodiments and comparative examples.
[0048] Example 1 Preparation of gradient fluorinated modified activated carbon: The activated carbon substrate was dried at 120℃ for 4h; it was placed in a fluorination reactor, and a mixed gas of HF:N2=50:250 was initially introduced and kept at 150℃ for 2h; the ratio was successively adjusted to 100:200, 150:150, and 250:50, and kept at 1.5h for each stage; finally, pure HF was introduced and kept at 220℃ for 3h; nitrogen was purged and cooled to room temperature to obtain gradient fluorinated modified activated carbon.
[0049] Purification process: Industrial-grade R134a is fed into the primary condenser, condensing at a specific temperature. At 15℃ and 0.40MPa, non-condensable gases are removed; the liquid crude product is pumped into a degassing tower at 1.0MPa, bottom temperature 45℃, and top temperature 25℃ to remove light components; the bottom material is fed into a distillation column at 0.7MPa, bottom temperature 50℃, and top temperature 40℃ to remove fluorocarbon isomers such as R134; the top product is condensed in a finished product condenser and enters an adsorber at 0.6MPa and 25℃, where it is filled with the aforementioned gradient fluorinated modified activated carbon to deeply remove R1122 and moisture; qualified products are collected in a pharmaceutical-grade finished product tank.
[0050] Material characterization: Surface area and porosity were measured using a fully automated specific surface area and porosity analyzer. In Example 1, the micropore size of the gradient fluorinated carbon was concentrated in the range of 0.68-0.85 nm, with a BET specific surface area of 920 m². 2 / g; X-ray photoelectron spectroscopy (XPS) shows a distinct F1s characteristic peak at 687 eV (e.g., Figure 2 As shown), confirming C F covalent bonds were successfully introduced; continuous breakthrough experiments (feed R1122=12ppm), breakthrough time 420h.
[0051] Breakthrough experiment: 20g of the gradient fluorinated modified activated carbon prepared in Example 1 was packed into a stainless steel adsorption column with an inner diameter of 15mm (bed height approximately 300mm). The adsorption was carried out at 25℃ and 0.6MPa with a space velocity (GHSV) of 400h⁻¹. -1 Liquid R134a containing 12.3 ppm R1122 was introduced. The outlet was continuously monitored using an online gas chromatograph. The experiment was repeated three times, and the breakthrough times (outlet R1122 ≥ 1 ppm) were 418 h, 422 h, and 420 h, respectively, with an average of 420 h and a standard deviation of 2 h.
[0052] Figure 3 This is a gas chromatogram of industrial-grade R134a, the raw material used in this embodiment. Figure 4 This is a gas chromatogram of the pharmaceutical grade R134a product obtained after the above purification process in this embodiment.
[0053] Example 2 Preparation of gradient fluorinated modified activated carbon: The activated carbon substrate was dried at 100℃ for 4h; it was placed in a fluorination reactor, and a mixed gas of HF:N2=50:250 (volume ratio) was initially introduced and kept at 120℃ for 2h; the ratio was successively adjusted to 100:200, 150:150, and 250:50, and kept at 1h for each stage; finally, pure HF was introduced and kept at 200℃ for 3h; nitrogen was purged and cooled to room temperature to obtain gradient fluorinated modified activated carbon.
[0054] Purification process: Industrial-grade R134a is fed into a primary condenser at a condensation temperature of -20℃ and an operating pressure of 0.35MPa to remove non-condensable gases; the liquid crude product is pumped into a degassing tower at an operating pressure of 0.8MPa, a bottom temperature of 35℃, and a top temperature of 15℃ to remove light components; the bottom material is fed into a distillation column at an operating pressure of 0.5MPa, a bottom temperature of 40℃, and a top temperature of 30℃ to remove isomers such as R134; the gas phase at the top of the column is condensed in a product condenser and enters an adsorber at an operating pressure of 0.4MPa and a temperature of 10℃, where it is filled with the aforementioned gradient fluorinated modified activated carbon to deeply remove R1122 and moisture; qualified products are collected in a pharmaceutical-grade finished product tank.
[0055] Test results: R134a purity 99.99%, R134 content 3ppm, R1122 <1ppm, moisture 2.8ppm, non-condensable gas 0.22%, meeting the pharmaceutical excipient grade indicators.
[0056] Example 3 Preparation of gradient fluorinated modified activated carbon: The activated carbon substrate was dried at 120℃ for 6h; it was placed in a fluorination reactor, and a mixed gas of HF:N2=50:250 (volume ratio) was initially introduced and kept at 160℃ for 3h; the ratio was successively adjusted to 100:200, 150:150, and 250:50, and kept at 2h for each stage; finally, pure HF was introduced and kept at 240℃ for 4h; nitrogen was purged and cooled to room temperature to obtain gradient fluorinated modified activated carbon.
[0057] Purification process: Industrial-grade R134a is fed into a primary condenser at a condensation temperature of -10℃ and an operating pressure of 0.45MPa to remove non-condensable gases; the liquid crude product is pumped into a degassing tower at an operating pressure of 1.4MPa, a bottom temperature of 60℃, and a top temperature of 40℃ to remove light components; the bottom material is fed into a distillation column at an operating pressure of 1.2MPa, a bottom temperature of 60℃, and a top temperature of 50℃ to remove isomers such as R134; the gas phase at the top of the column is condensed in a product condenser and enters an adsorber at an operating pressure of 1.0MPa and a temperature of 40℃, where it is filled with the aforementioned gradient fluorinated modified activated carbon to deeply remove R1122 and moisture; qualified products are collected in a pharmaceutical-grade finished product tank.
[0058] Test results: R134a purity 99.99%, R134 content 3ppm, R1122 < 1ppm, moisture 2.5ppm, non-condensable gas 0.20%, meeting the pharmaceutical excipient grade indicators.
[0059] Comparative Example 1 The difference from Example 1 is that the adsorber is filled with unmodified ordinary activated carbon and does not undergo any fluorination treatment, while the other process parameters and operating conditions are exactly the same.
[0060] Material characterization: XPS spectrum of unmodified activated carbon in Comparative Example 1 is shown below. Figure 2As shown, only C and O elements were detected in its full spectrum, and no F1s characteristic peak was observed, confirming that its surface does not contain fluorine and lacks chemically active sites that interact polarly with R1122.
[0061] Comparative Example 2 The difference from Example 1 is that the activated carbon is fluorinated in a one-step constant ratio, with HF:N2=100:200. There is no gradient increase of the HF ratio, no deep fluorination step with pure HF, and the other process conditions are exactly the same.
[0062] Material characterization: Comparative Example 2 showed a broadened pore size distribution with an average pore size of 1.52 nm, micropore collapse, and a decrease in specific surface area to 580 m². 2 / g; No obvious F1s characteristic peak.
[0063] Comparative Example 3 The process sequence was adjusted to: initial separation and condensation → degassing tower → adsorber → distillation tower → finished product; the remaining equipment, activated carbon (same as graded fluorinated carbon in Example 1), and operating parameters are the same as in Example 1.
[0064] Results: R1122 residue was 4.8 ppm after removal, which did not meet the requirement of <1 ppm; activated carbon showed breakthrough after 80 hours of operation, and its lifespan was only 1 / 4 of that in Example 1.
[0065] Heavy components and high-boiling-point substances enter the adsorber prematurely, occupying active sites and clogging pores, leading to the failure of targeted adsorption.
[0066] Comparative Example 4 Activated carbon preparation: The rest is the same as in Example 1, except that the deep fluorination temperature of pure HF is increased to 300℃ and held at that temperature for 3 hours. The purification process is the same as in Example 1.
[0067] Results: R1122 residue was 5.7 ppm, which did not meet the standard; BET showed that a large number of micropores collapsed, and the average pore size increased to 1.6 nm.
[0068] Fluorination temperatures exceeding 240°C result in severe etching that destroys the 0.6-0.9 nm sieve channels, leading to a loss of size selectivity for R1122.
[0069] Test results The purity of R134a, the content of R134, and the content of R1122 in Examples 1-3 and Comparative Examples 1-4 were determined by gas chromatography (GC), and the moisture content was determined by Karl Fischer method. The results are shown in Table 1.
[0070] The gas chromatographic peaks of industrial grade R134a used in Example 1 are shown in Table 2.
[0071] Table 1: Test results of Examples 1-3 and Comparative Examples 1-4
[0072] As shown in Table 1, the gradient fluorination modified activated carbon of this invention can remove R1122 from 12.3 ppm to below 1 ppm, reduce moisture to 2.6 ppm, and increase the purity of R134a to 99.99%, meeting the requirements for pharmaceutical excipient grade. Ordinary activated carbon and one-step fluorination activated carbon have poor removal effects on R1122 and cannot meet the standards.
[0073] Table 2: Gas chromatographic peaks of industrial-grade R134a used in Example 1
Claims
1. A method for purifying pharmaceutical-grade R134a, characterized in that, Includes the following steps: (1) The industrial grade R134a crude raw material is fed into the primary condenser for condensation treatment to remove non-condensable gases and obtain liquid crude product. (2) The liquid crude product is fed into a degassing tower for distillation and degassing to remove light component impurities; (3) The material after the removal of light components is fed into the distillation column for deep distillation to remove heavy components and fluorocarbon isomer impurities, and the gaseous product is obtained from the top of the distillation column; (4) After the gaseous product is condensed into a liquid phase, it is fed into an adsorber filled with gradient fluorinated modified activated carbon for deep adsorption, selectively removing R1122 impurities and moisture to obtain the pharmaceutical excipient grade R134a product. The preparation method of the gradient fluorination modified activated carbon includes: using activated carbon as a substrate, pretreating it with a mixed gas of hydrogen fluoride and nitrogen; then gradually increasing the proportion of hydrogen fluoride and decreasing the proportion of nitrogen in the introduced gas in stages to carry out gradient concentration and temperature increase modification; finally switching to pure hydrogen fluoride gas for deep fluorination treatment at 200-240℃, and obtaining the gradient fluorination modified activated carbon after cooling. The specific preparation steps of the gradient fluorination modified activated carbon are as follows: S1. Dry the activated carbon at 100-120℃ for 4-6 hours; S2. The mixture of HF and N2 with a volume ratio of 50:250 is introduced into the fluorination reactor and pretreated at 120-160℃ for 2-3 hours. S3. Adjust the volume ratio of the mixed gas to HF:N2 = 100:200, 150:150, and 250:50 in stages, and keep it heated for 1-2 hours in each stage. S4. Finally, switch to pure HF gas and keep at 200-240℃ for deep fluorination for 3-4 hours. S5. After the reaction is complete, purge with nitrogen and cool to room temperature; The modified activated carbon prepared by the gradient fluorination has CF bonds formed on its surface and its pore size distribution is controlled in the range of 0.6-0.9 nm, which matches the molecular dynamics diameter of R1122. It achieves targeted and specific adsorption of R1122 through a dual mechanism of size sieving and polar adsorption.
2. The purification method for pharmaceutical excipient grade R134a according to claim 1, characterized in that, The specific operation parameters for steps (1)-(3) are as follows: In step (1), the temperature of the condensation treatment is controlled at -10 to 20°C, and the pressure is controlled at 0.35 to 0.45 MPa; In step (2), the operating pressure of the degassing tower is controlled at 0.8-1.4 MPa, the bottom temperature is controlled at 35-65℃, and the top temperature is controlled at 15-45℃. In step (3), the operating pressure of the distillation column is controlled at 0.5-1.2 MPa, the bottom temperature is controlled at 40-60℃, and the top temperature is controlled at 30-50℃.
3. The purification method for pharmaceutical excipient grade R134a according to claim 1, characterized in that, In step (4), the operating pressure of the adsorber is controlled at 0.4-1.0 MPa and the operating temperature is controlled at 10-40℃. The product after adsorption by the adsorber is tested online. The qualified product is collected into the finished product tank, and the unqualified product is sent back to the degassing tower as reflux material for further purification.
4. A purification apparatus for pharmaceutically excipient-grade R134a used to implement the method according to any one of claims 1-3, characterized in that, The product includes an industrial-grade R134a finished product tank (1), a primary separator condenser (2), a feed pump (3), a degassing tower (4), a distillation tower (5), a finished product condenser (6), an adsorber (7), and a pharmaceutical-grade finished product tank (8), which are connected in sequence by pipelines. The upper inlet of the primary condenser (2) is connected to the industrial-grade R134a finished product tank (1), and the lower outlet is connected to the degassing tower (4) via the feed pump (3). The bottom outlet of the degassing tower (4) is connected to the inlet of the distillation tower (5), the top outlet of the distillation tower (5) is connected to the finished product condenser (6), and the bottom outlet of the finished product condenser (6) is connected to the adsorber (7). The adsorber (7) is filled with the gradient fluorinated modified activated carbon as described in claim 1.
5. The purification apparatus for pharmaceutical excipient grade R134a according to claim 4, characterized in that: The upper outlet pipeline of the adsorber (7) is divided into two paths. The first path is connected to the pharmaceutical excipient-grade finished product tank (8) and is used to transport qualified products. The second path serves as the return line for unqualified products and is connected back to the degassing tower (4).
6. The purification apparatus for pharmaceutical excipient grade R134a according to claim 4, characterized in that: Both the degassing tower (4) and the distillation tower (5) are equipped with sampling ports for real-time monitoring of the composition and quality of the gas and liquid phase materials.
Citation Information
Patent Citations
An isocyanate-based polymer foam composite with improved thermal insulation properties
CN103826853A
Purification system and purification method of electronic-grade octafluorocyclobutane
CN116212431A
